ArticleBlood neoplasia2024

Real-world comparison of daratumumab-based regimens in relapsed/refractory multiple myeloma using health record data.

Benjamin A Derman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.